MedTrace Logo

Arterial Disease Multifactorial Intervention Trial (ADMIT)

NCT00000539 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2016-07-12

No results posted yet for this study

Summary

To evaluate, in asymptomatic and symptomatic participants with peripheral arterial disease, the feasibility of recruitment and adherence, efficacy and safety of HDL-C raising along with effective control of LDL-C levels, antioxidant therapy, antithrombotic therapy, and their combinations.

Conditions

Interventions

DRUG

niacin

DRUG

pravastatin

DRUG

beta-carotene

DRUG

vitamin E

BEHAVIORAL

dietary supplements

DRUG

vitamin C

DRUG

warfarin

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • Kathryn Davis · Statistics and Epidemiology Research Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1992-09-30
Completion
1999-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000539 on ClinicalTrials.gov